Nihon Ishinkin Gakkai Zasshi
Online ISSN : 2434-5237
Print ISSN : 2434-5229
Current issue
Showing 1-2 articles out of 2 articles from the selected issue
  • Shigeru Kohno, Koichi Izumikawa, Minoru Yoshida, Fumito Okada, Takehik ...
    2020 Volume 61 Issue 1 Pages 1-11
    Published: 2020
    Released: February 29, 2020
    Supplementary material
    Background: Posaconazole (PSCZ) is a broad-spectrum azole antifungal drug that shows potent antifungal activity to filamentous fungi and yeast-like fungi including Mucorales.
    Objective and Method: A randomized, active-controlled, open-label, comparative study to assess the safety and efficacy of PSCZ in Japanese subjects with deep-seated fungal infection was conducted (MK-5592 Protocol 101, Identifier: NCT02180165). Subjects with aspergillosis were randomized at 2:1 ratio to PSCZ (57 subjects) or voriconazole (VRCZ, 27) and subjects with mucormycosis were allocated to PSCZ (3), and received study therapy at a maximum of 84 days. The overall response was assessed at Day 42, Day 84, or the end of treatment, and adverse events were followed up to 14 days after the end of treatment.
    Results: The overall response rates were 40.0% (2/5) for PSCZ and 100.0% (3/3) for VRCZ in invasive aspergillosis (at Day 42), 58.3% (28/48) for PSCZ and 87.0% (20/23) for VRCZ in chronic pulmonary aspergillosis (at Day 84), and 100.0% (3/3) for PSCZ in mucormycosis (at end of treatment) respectively. The common drug-related adverse events were pyrexia (22.8%), hypokalemia (15.8%), hepatic function abnormality (14.0%), and hypertension (14.0%) in PSCZ; and photophobia (29.6%), visual impairment (14.8%), and hepatic function abnormality (14.8%) in VRCZ.
    Conclusion: PSCZ was shown to be safe and effective in Japanese patients with aspergillosis and mucormycosis, pointing to its usefulness against fungal infections with limited treatment choices in Japan.
    Download PDF (1318K)